TSHA-120 is currently being evaluated in an ongoing open-label, nonrandomized, dose-escalation clinical trial conducted by the U.S. National Institute of Neurological Disorders and Stroke (NINDS) division of the National Institutes of Health (NIH). The primary end point is safety, and a primary measure of TSHA-120's clinical efficacy is the Motor Function Measure 32 (MFM32) score. TSHA-120 has demonstrated the potential to improve MFM32 scores in patients. Additional data from the study are expected later this year.

TSHA-120 received rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration for the treatment of giant axonal neuropathy, a rare inherited genetic disorder that affects the central and peripheral nervous system and is caused by loss-of-function mutations in the gene coding for gigaxonin.

Before the end of 2021, Taysha intends to request an end-of-phase meeting with the FDA and engage with the European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to discuss the regulatory pathway for TSHA-120.

Under the agreement, in exchange for granting Taysha the exclusive worldwide rights to TSHA-120, a leading giant axonal neuropathy patient advocacy group will receive an upfront payment of $5.5 million and will be eligible to receive clinical, regulatory, and commercial milestones totaling up to $19.3 million, as well as a low, single-digit royalty on net sales upon commercialization of the product.

Taysha establishes additional collaboration for minigene payloads
Taysha Gene Therapies has established a multiyear collaboration with a team of Yale University researchers. The goal is to advance next-generation minigene...

Taysha collaborates on minigene payloads for AAV gene therapy
Taysha Gene Therapies has established multiyear collaborations with the Cleveland Clinic and the University of Texas Southwestern Gene Therapy Program...

Taysha, UTSW start fund to speed up CNS gene therapies
Taysha Gene Therapies and the University of Texas Southwestern Medical Center (UTSW) have launched a fund to accelerate the development of adeno-associated...

AllStripes, Taysha Gene Therapies partner on rare disease gene therapy program
AllStripes and Taysha Gene Therapies have entered a multiyear collaboration focused on advancing the development of TSHA-104, an adeno-associated virus...

Taysha nabs rare pediatric disease, orphan drug status
Taysha Gene Therapies has received rare pediatric disease designation and orphan drug designation from the U.S. Food and Drug Administration for TSHA-104,...